Replies to post #4472 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

I don't think Opul termination is the main issue insofar as the increase in GAAP expenses due to Opul termination is mostly a non-cash impairment charge. Please see #msg-172850997 for my explanation of today's selloff.

[vinmantoo]

I added shares in the 11's.

Investing can be gut-wrenching, especially at times like these. The people who have been critical of management have been proven right.

So what to do now with a company with a superior product but a management which has repeatedly fumbled. I guess the real question for investors are, 1) is management FINALLY on the right course in aesthetics with price reductions and the Daxxi lite options, and 2) will Daxxify penetration into the CD go better than aesthetics did?

I am not as brave or confident as you 10nisman but I did buy a bit more at $12.85. Let the cards fall where they may but I have a long time line.